2-(4-(Biphenyl-4-ylamino)-6-chloropyrimidin-2-ylthio)octanoic acid (HZ52) – a novel type of 5-lipoxygenase inhibitor with favourable molecular pharmacology and efficacy in vivo

Por Greiner, C, Hörnig, C, Rossi, A, Pergola, C, Zettl, H, Schubert-Zsilavecz, M, Steinhilber, D, Sautebin, L, Werz, O
Publicado em 2011

Kernel learning for ligand-based virtual screening: discovery of a new PPARγ agonist

Por Rupp, Matthias, Schroeter, T, Steri, R, Proschak, Ewgenij, Hansen, K, Zettl, H, Rau, O, Schubert-Zsilavecz, M, Müller, K-R, Schneider, Gisbert
Publicado em 2010

A pirinixic acid derivative (LP105) inhibits murine 5-lipoxygenase activity and attenuates vascular remodelling in a murine model of aortic aneurysm

Por Revermann, M, Mieth, A, Popescu, L, Paulke, A, Wurglics, M, Pellowska, M, Fischer, AS, Steri, R, Maier, TJ, Schermuly, RT, Geisslinger, G, Schubert-Zsilavecz, M, Brandes, RP, Steinhilber, D
Publicado em 2011

Molecular pharmacological profile of a novel thiazolinone-based direct and selective 5-lipoxygenase inhibitor

Por Hofmann, B, Rödl, CB, Kahnt, AS, Maier, TJ, Michel, AA, Hoffmann, M, Rau, O, Awwad, K, Pellowska, M, Wurglics, M, Wacker, M, Živković, A, Fleming, I, Schubert-Zsilavecz, M, Stark, H, Schneider, G, Steinhilber, D
Publicado em 2012